Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tanibirumab for recurrent glioblastoma
ACTRN12615001156572Phase 2Completed
- Sponsor
- PharmAbcine
- Start
- Feb 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of olinvacimab in glioblastoma (GBM) (3 arms), sponsored by PharmAbcine. Primary endpoint: Safety of tanibirumab. Started Feb 2016; status: completed.
02
Drugs
olinvacimab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on ACTRN12615001156572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12615001156572.